Legal loopholes and poor enforcement let criminals in China divert APIs for illegal drug production according to a US congressional committee which says the country is fast becoming the major global supplier of crystal meth precursors.
The cold chain solution company, CSafe, has opened a new San Juan-based service center in conjunction with the launch of its new company, CSafe Puerto Rico LLC.
eClinicalHealth and Clinerion have announced a collaboration under which the companies will offer their complementary technologies jointly to hospitals and sponsor companies/CROs.
The US FDA’s decision to let Juno Therapeutics restart its JCAR015 trial is positive, but the CAR-T sector must learn from safety and efficacy findings says French biotech TxCell.
Researchers suggest targeted nanosystem drug delivery could be the key to crossing gastrointestinal tract and blood-brain barriers – a prevailing issue with oral medications.
The independent lab network has combined 11 of its brands, including ABC Laboratories, to reside under a single company in order to “leverage cross functional capabilities,” says CEO.
Private equity fund Apax Partners will take control of Spanish API manufacturer Inke when it completes the acquisition of Invent Farma later this year.
Senior leadership from key regulatory bodies gathered at the DIA 2016 Annual Meeting to discuss challenges they face as global regulators, both domestically and as part of international cooperative initiatives.
The Precision Medicine Initiative (PMI) Cohort Program is expected to launch later this year with the goal of enrolling more than one million US participants by 2020.
The FDA has placed on clinical hold on Juno’s Ph II clinical trial of JCAR015 following the death of two patients last week and will “continue to work” to ensure patient safety, says representative.
In their pursuit to apply criminology theory to counterfeit medications, Nigerian leaders faced death, says researcher – but the country's efforts have ultimately been successful.
With deadlines around the corner, companies are beginning to plan their serialization initiatives – a process defined by regulatory changes, says Antares Vision.
CrownBio’s new stable cell lines feature various immune checkpoints and receptors which are key targets and pathways for oncology drug discovery and development.
The Council of the EU has unveiled a plan to analyse the competitive landscape for pharmaceuticals in Europe in a bid to improve patients' access to medicines.
Japan's Astellas has agreed to carry out clinical trials of a vaccine for serious diarrhoeal diseases which does not need to be refrigerated or injected and is produced in transgenic rice plants.
UK biopharma company Scancell was forced to halt trials of its flagship cancer immunotherapy SCIB1 because its supplies of the drug no longer meet quality specifications.
A transdermal patch formulation of the most commonly used Alzheimer's disease (AD) drug could be on the market in 2019 - two to three years earlier than expected.
The pharma industry could learn valuable lessons from the aerospace and automotive industries when it comes to designing new products, according to Swiss researchers.
Almost one in five active pharmaceutical ingredient (API) facilities inspected by the European Directorate for Quality of Medicines and Healthcare (EDQM) last year failed to meet quality standards.
As electronic patient reported outcomes (ePRO) become more prevalent, the adoption of Bring Your Own Device in clinical trials “won’t be far behind,” says Bracket.
An oncology centre to support the Moonshot Initiative, conflict-of-interest guidance and calls to become independent. Welcome to in-Pharmatechnologist’s US FDA round-up.
Researchers supported by the National Institutes of Health (NIH) have developed a clinical-grade stem cell line, which will help accelerate early-stage clinical research.
